top of page
NEUROMITY
Home
About Us
Leadership
Scientific Advisory Board
Lead Program
Portfolio Strategy
More
Use tab to navigate through the menu items.
Contact Us
NTY-184 Portfolio Strategy
Expedited, de-risked 505(b)(2) pathway to MDD and other bupropion indications, plus value expansion with new indications and combination products.
NEXT: CONTACT US â–º
bottom of page